Kingswood Wealth Advisors’s Elicio Therapeutics ELTX Stock Holding History

Kingswood Wealth Advisors’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$148K	Buy	+13,800	New	+$133K	0.01%	897

Other funds holding ELTX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Kingswood Wealth Advisors's ELTX Position: Q1 2026 in Review

Kingswood Wealth Advisors opened a new position in Elicio Therapeutics (ELTX) in Q1 2026: 13,800 shares worth $148K. The stake represents 0.01% of the portfolio and ranks #897 among its holdings.

47 funds tracked by Wall St. Rank hold ELTX as of Q1 2026.

Kingswood Wealth Advisors held 13,800 shares of Elicio Therapeutics worth $148K as of Q1 2026.
Elicio Therapeutics was a new Kingswood Wealth Advisors position in Q1 2026.
Elicio Therapeutics made up 0.01% of Kingswood Wealth Advisors's portfolio in Q1 2026, its #897 holding.
47 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q1 2026.

Based on Kingswood Wealth Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.